Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Henri Becquerel
About this trial
The goal of the study lies in offering a multimodal analysis of the post-therapeutic response based on both quantitative parameters and radiomics (CT, MRI, and PET imaging), and on tumor biology, in particular the hypersensitive detection of tumor DNA.
Eligibility criteria
Qualifiers
Patient with squamous cell carcinoma of the oropharynx (cT2-cT4) or squamous cell carcinoma of the oral cavity (cT2-cT4)
With lymph node involvement (cN1, cN2, or cN3) (confirmation of lymph node involvement after review of imaging in CCP and without histological confirmation required)
Eligible for curative treatment with cisplatin-based chemoradiotherapy alone (100 mg/m2 every 3 weeks or 40 mg/m2 weekly)
Regardless of p16 status
Disqualifiers
Head and neck squamous cell carcinomas in other locations (salivary gland, larynx, hypopharynx, cavum, sinuses)
Primary squamous cell carcinoma of the lymph nodes
History of radiotherapy to the head and neck region
Radiochemotherapy not based on the use of cisplatin
Trial design
Treatments tested in this trial
- Multimodal approach
Treatment groups
152 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov